HPN-100 + Placebo

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cirrhosis

Conditions

Cirrhosis, Hepatic Encephalopathy

Trial Timeline

Dec 1, 2009 → Apr 1, 2012

About HPN-100 + Placebo

HPN-100 + Placebo is a phase 2 stage product being developed by Amgen for Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00999167. Target conditions include Cirrhosis, Hepatic Encephalopathy.

What happened to similar drugs?

6 of 11 similar drugs in Cirrhosis were approved

Approved (6) Terminated (0) Active (5)

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00999167Phase 2Completed

Competing Products

20 competing products in Cirrhosis

See all competitors
ProductCompanyStageHype Score
SYNB1020SynlogicPhase 1/2
14
peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirinChugai PharmaceuticalPhase 3
40
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)ShionogiPhase 2
35
Mesenchymal Stem CellRohto PharmaceuticalPre-clinical
26
Bumetanide + FurosemideJohnson & JohnsonPhase 3
47
Mesenchymal stem cellRohto PharmaceuticalPhase 1/2
32
ZibotentanAstraZenecaPhase 1
29
Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part A: zibotentan (dose B) + dapagliflozin + Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part B: placebo (matching zibotentan capsule) + dapagliflozin + Part B: zibotentan (dose A) + dapagliflozin + Part B: zibotentan (dose B) + dapagliflozin + Part B: zibotentan (dose C) + dapagliflozinAstraZenecaPhase 2
27
Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) + Zibotentan + placebo (placebo matching dapagliflozin tablet) + Zibotentan + dapagliflozinAstraZenecaPhase 2
35
ARQ 197MerckPhase 1
29
Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBVMerckApproved
39
Steroids + Basiliximab + Tacrolimus + Enteric-coated Mycophenolic acid (EC-MPA)NovartisApproved
43
Telbivudine + Enecavir + AdefovirNovartisApproved
39
Serelaxin + PlaceboNovartisPhase 2
35
Terlipressin acetate + Serelaxin (RLX030)NovartisPhase 2
35
PasireotideNovartisPhase 1
29
Placebo Comparator + Experimental: Seladelpar 50 mg + Experimental: Seladelpar / MBX-8025 200 mgGilead SciencesPhase 2
27
TDF/FTC/LPV/r + PlaceboGilead SciencesPre-clinical
18
MBX-8025 2 mg Capsule + MBX-8025 5 mg Capsule + MBX-8025 10 mg CapsuleGilead SciencesPhase 2
35
Seladelpar 5 mg Capsule + Seladelpar 10 mg CapsuleGilead SciencesPhase 3
44